3.239.4.127
dgid:
enl:
npi:0
Gastroenterology
Journal Scan

Real-Word Benefits With Teduglutide Treatment of Short Bowel Syndrome

Posted on

Teduglutide, a recombinant analog of glucagon-like peptide-2 (GLP-2), has been approved since 2012 as a treatment for patients with short bowel syndrome who are dependent on parenteral support. GLP-2 helps regulate the growth, proliferation, and maintenance of cells lining the gastrointestinal tract, thereby improving absorption of fluids and nutrients and decreasing the need for parenteral support. It has been unclear whether the benefits observed with teduglutide in clinical trials would be maintained in real-world settings; however, a recent retrospective review by German investigators found the drug to induce functional and structural changes that led to a gradual reduction of parenteral support at no cost to patients’ body composition. Their results also suggested improved intestinal function with a compensatory effect on nutritional status.

Read more here.

Reference

Pevny S, Maasberg S, Rieger A, et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin Nutr. 2018 Aug 2. pii: S0261-5614(18)31243-3. doi: 10.1016/j.clnu.2018.07.030.

-Advertisement-
Related Articles
$9.1M Awarded for Liver Cancer Research
Feb 26, 2021
FDA Approves Epclusa for Pediatric HCV
Jun 01, 2020
Liver Cancer Rates Increase in Developed Countries
May 18, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-